Stay updated with breaking news from Eric Blouin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The industry awaits a number of readouts and approvals for drugs that address market gaps and enrich treatment landscapes — with huge sales potential to boot.
The past two years were all about COVID-19 vaccines and therapeutics. Now, imminent approvals in oncology, hematology and autoimmune disorders are set to enhance patient convenience.
Therapies in the oncology, neurology and autoimmune disease pipelines could soon pose challenges to existing standards of care.